SAGA Diagnostics has commercially launched the multi-cancer molecular residual disease (MRD) platform, Pathlight, in the US.

The CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically ...

The US Food and Drug Administration (FDA) has granted approval for Abbott's Tendyne transcatheter mitral valve replacement ...

Danish medtech Brainreader has secured $7.3m (€6.6m) to support the market rollout of Neuroreader, its artificial ...

With the 78th World Health Assembly ending today, all eyes have been on this year’s World Health Organization (WHO) member’s ...

SeekIn has announced the clinical validation of its SeekInCare blood test, intended for the early identification of various ...

Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by ...

Surgify Medical has secured €7m ($7.97m) in Series A funding to expand the reach of its Surgify Halo technology.

Zylox-Tonbridge Medical Technology has received regulatory approval for its ZYLOX Unicorn vascular closure device (VCD) in ...

A team at the University of Melbourne has developed a new blood test for the diagnosis of rare genetic diseases in babies and ...

Neurostimulation is reshaping the treatment of urinary incontinence, offering minimally invasive relief through smarter and ...

Roche is set to partner with Broad Clinical Labs for developing pilot applications leveraging its next-generation sequencing ...